Compare Amgen, Inc. (AMGN) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Boston Beer Company Inc — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Boston Beer Company Inc trades at $176.79 (market cap $1.84B). The key difference: Amgen, Inc. is far larger — about 106.6× Boston Beer Company Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| AMGN | SAM | |
|---|---|---|
Market Cap | $196.12B | $1.84B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $260.05 |
52-Week Low | $271.18 | $161.08 |
Enterprise Value | $241.41B | $1.71B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SAM trades at $176.79, up 1.1% on the day, amid a bearish technical signal but with a consensus analyst price target of $222.67 suggesting upside. Recent earnings show volatility with a Q1 2026 miss, while full-year 2025 net income improved to $108.47M. Cash flow remains positive, but 2026 revenue and profit projections indicate challenges. The company is investing in brand innovation and Beyond Beer expansion to drive growth.
The outlook is mixed; valuation ratios appear reasonable, and strategic initiatives support long-term potential, but near-term volume pressure and negative 2026 profit forecasts pose risks. Investor sentiment is cautious, with most analysts rating Hold. Key catalysts include execution on cost savings and brand momentum against a competitive backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
